Login / Signup

Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer's disease: a cross-sectional analysis from the SILCODE study.

Can ShengKun YangBeiqi HeWenying DuYanning CaiYing Han
Published in: Alzheimer's research & therapy (2022)
This study has been registered in ClinicalTrials.gov (NCT03370744, https://www.clinicaltrials.gov ) in November 15, 2017.
Keyphrases
  • stem cells
  • cognitive decline
  • risk assessment
  • cell therapy